moxifloxacin has been researched along with albuterol in 8 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (albuterol) | Trials (albuterol) | Recent Studies (post-2010) (albuterol) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 10,108 | 3,059 | 2,058 |
| Protein | Taxonomy | moxifloxacin (IC50) | albuterol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.2618 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Megjhani, M; Shahzad, S; Suryanarayanan, M; Vasudevan, VP | 1 |
| Muccioli, GG; Tulkens, PM; Van Bambeke, F; Vandevelde, NM | 1 |
1 review(s) available for moxifloxacin and albuterol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for moxifloxacin and albuterol
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Mycoplasma pneumoniae bronchiolitis mimicking asthma in an adult.
Topics: Adult; Albuterol; Anti-Infective Agents; Asthma; Aza Compounds; Bronchiolitis; Bronchodilator Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Mycoplasma; Quinolines; Steroids | 2012 |
Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms.
Topics: Aged; Aged, 80 and over; Albuterol; Anti-Bacterial Agents; Biofilms; Bronchodilator Agents; Chromatography, High Pressure Liquid; Drug Interactions; Female; Fluoroquinolones; Humans; Ipratropium; Macrolides; Male; Mass Spectrometry; Microbial Viability; Middle Aged; Models, Theoretical; Moxifloxacin; N-Acetylneuraminic Acid; Pneumococcal Infections; Streptococcus pneumoniae; Triazoles | 2015 |